G Dranoff

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
    Immunol Rev 222:287-98. 2008
  2. pmc Deficiencies of GM-CSF and interferon gamma link inflammation and cancer
    Thomas Enzler
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 197:1213-9. 2003
  3. pmc Inciting inflammation: the RAGE about tumor promotion
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Exp Med 205:267-70. 2008
  4. pmc IAP inhibitors enhance co-stimulation to promote tumor immunity
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 207:2195-206. 2010
  5. doi request reprint Tailor-made renal cell carcinoma vaccines
    Glenn Dranoff
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Cell 22:287-9. 2012
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  7. ncbi request reprint Cytokines in cancer pathogenesis and cancer therapy
    Glenn Dranoff
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 4:11-22. 2004
  8. ncbi request reprint GM-CSF-based cancer vaccines
    Glenn Dranoff
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Immunol Rev 188:147-54. 2002
  9. doi request reprint Experimental mouse tumour models: what can be learnt about human cancer immunology?
    Glenn Dranoff
    Department of Medical Oncology and the Cancer Vaccine Center, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Immunol 12:61-6. 2012
  10. pmc Coordinated tumor immunity
    Glenn Dranoff
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 510E, 44 Binney Street, Boston, MA 02115, USA
    J Clin Invest 111:1116-8. 2003

Research Grants

  1. Targeting MFG-E8 as Melanoma Immunotherapy
    Glenn Dranoff; Fiscal Year: 2010
  2. Targeting MFG-E8 as Melanoma Immunotherapy
    Glenn Dranoff; Fiscal Year: 2011
  3. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2001
  4. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2006
  5. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2009
  6. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2007
  7. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2004
  8. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2003
  9. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2002
  10. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2000

Detail Information

Publications64

  1. doi request reprint Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
    Immunol Rev 222:287-98. 2008
    ..Together, these results define key regulatory circuits that attenuate immune-mediated tumor destruction and suggest novel combinatorial therapies that might enhance the clinical activity of GM-CSF-secreting tumor cell vaccines...
  2. pmc Deficiencies of GM-CSF and interferon gamma link inflammation and cancer
    Thomas Enzler
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 197:1213-9. 2003
    ..These findings demonstrate that the interplay of infectious agents with cytokine-mediated regulation of immune homeostasis is a critical determinant of cancer susceptibility...
  3. pmc Inciting inflammation: the RAGE about tumor promotion
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Exp Med 205:267-70. 2008
    ..New data show that feed-forward signals downstream of the receptor for advanced glycation end-products (RAGE) can fuel chronic inflammation, creating a microenvironment that is ideal for tumor formation...
  4. pmc IAP inhibitors enhance co-stimulation to promote tumor immunity
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Exp Med 207:2195-206. 2010
    ....
  5. doi request reprint Tailor-made renal cell carcinoma vaccines
    Glenn Dranoff
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer Cell 22:287-9. 2012
    ..A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into these central issues...
  6. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  7. ncbi request reprint Cytokines in cancer pathogenesis and cancer therapy
    Glenn Dranoff
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 4:11-22. 2004
  8. ncbi request reprint GM-CSF-based cancer vaccines
    Glenn Dranoff
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Immunol Rev 188:147-54. 2002
    ..The formulation of simplified methods for manufacturing autologous, GM-CSF-secreting tumor cells has enabled more extensive clinical testing in diverse patient settings...
  9. doi request reprint Experimental mouse tumour models: what can be learnt about human cancer immunology?
    Glenn Dranoff
    Department of Medical Oncology and the Cancer Vaccine Center, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Immunol 12:61-6. 2012
    ..To accelerate the translation of these findings into clinical benefits, investigators need to gain a better understanding of the strengths and limitations of mouse model systems as tools for deciphering human antitumour immune responses...
  10. pmc Coordinated tumor immunity
    Glenn Dranoff
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 510E, 44 Binney Street, Boston, MA 02115, USA
    J Clin Invest 111:1116-8. 2003
  11. ncbi request reprint Cancer gene therapy: connecting basic research with clinical inquiry
    G Dranoff
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:2548-56. 1998
    ....
  12. ncbi request reprint GM-CSF-secreting melanoma vaccines
    Glenn Dranoff
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Oncogene 22:3188-92. 2003
    ....
  13. doi request reprint Targets of protective tumor immunity
    Glenn Dranoff
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann N Y Acad Sci 1174:74-80. 2009
    ..Our findings suggest that components of the NKG2D pathway may be attractive targets for therapeutic monoclonal antibodies...
  14. ncbi request reprint Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL
    S Li
    The Center for Blood Research, Dana-Farber Cancer Institute, and Harvard Institutes of Medicine and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA
    Blood 97:1442-50. 2001
    ..These results demonstrate that IL-3 and GM-CSF are not required for BCR/ABL-induced CML-like leukemia in mice and suggest that autocrine production of IL-3 does not play a role in established chronic phase CML in humans...
  15. ncbi request reprint Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity
    S Gillessen
    Department of Adult Oncology, Dana Farber Cancer Institute Harvard Medical School, Boston, MA, USA
    Blood 97:922-8. 2001
    ..Together, these findings delineate overlapping roles for GM-CSF and IL-3 in hematopoiesis and immunity. (Blood. 2001;97:922-928)..
  16. pmc CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
    X F Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:7492-7. 2001
    ..These findings suggest that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy...
  17. ncbi request reprint Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites
    C S Lantz
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 392:90-3. 1998
    ..These findings establish a role for IL-3 in immunity to parasites and indicate that one of the functions of IL-3 in host defence against infection is to expand populations of haematopoietic effector cells...
  18. ncbi request reprint Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines
    K Dunussi-Joannopoulos
    Dana Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Blood 91:222-30. 1998
    ..1-AML vaccines. These preclinical data emphasize that GM-CSF gene immunotherapy deserves clinical evaluation in AML...
  19. pmc CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 100:2757-65. 1997
    ..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy...
  20. ncbi request reprint Interpreting cancer vaccine clinical trials
    G Dranoff
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Gene Med 1:80-3. 1999
    ....
  21. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
  22. ncbi request reprint Cathepsin S required for normal MHC class II peptide loading and germinal center development
    G P Shi
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Immunity 10:197-206. 1999
    ..These results indicate cathepsin S is a major Ii-processing enzyme in splenocytes and dendritic cells. Its role in humoral immunity critically depends on how antigens access the immune system...
  23. ncbi request reprint Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
    M H Tomasson
    Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 97:1435-41. 2001
    ....
  24. ncbi request reprint Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy
    J C Schmollinger
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Apoptosis 9:309-13. 2004
    ..These findings demonstrate that ML-IAP can serve as a tumor rejection antigen, although additional vaccine targets will be required to circumvent immune escape and tumor heterogeneity...
  25. pmc MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Invest 117:1902-13. 2007
    ..These findings clarify the immunoregulatory effects of apoptotic cells and suggest new therapeutic strategies to modulate CD4(+) T cell subsets in cancer and autoimmunity...
  26. pmc Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:9190-5. 2006
    ..Moreover, these results highlight the therapeutic potential of anti-MICA antibodies to overcome immune suppression and effectuate tumor destruction in patients...
  27. ncbi request reprint Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis
    Darryl A Oble
    Department of Pathology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Am J Surg Pathol 32:1130-7. 2008
    ....
  28. doi request reprint Immune therapy for cancer
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Annu Rev Immunol 27:83-117. 2009
    ..The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments...
  29. pmc Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
    Jan C Schmollinger
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:3398-403. 2003
    ..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape...
  30. pmc CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion
    Silke Gillessen
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:8874-9. 2003
    ..DCs from immunized CD1d-deficient mice showed compromised maturation and function. Together, these results delineate a role for CD1d-restricted T cell-DC cross talk in the shaping of antitumor immunity...
  31. ncbi request reprint CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells
    Xiao Feng Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 62:5517-22. 2002
    ..Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy...
  32. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008
    ....
  33. pmc Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction
    Catia Fonseca
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:1681-8. 2009
    ..Together, these findings reveal the unexpected immunogenicity of PDIs and raise the possibility that these gene products might serve as targets for therapeutic monoclonal antibodies...
  34. pmc The biologic importance of tumor-infiltrating lymphocytes
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
    J Cutan Pathol 37:48-53. 2010
    ..These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights...
  35. pmc Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 15:6412-20. 2009
    ....
  36. pmc Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
    Thomas Enzler
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 110:954-61. 2007
    ..These results, together with previous reports of impaired hematopoietic responses to GM-CSF and IL-3 in patients with T1D and in NOD mice, indicate that functional deficiencies of these cytokines contribute to diabetes...
  37. ncbi request reprint MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients
    Joseph A Mollick
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Immun 3:3. 2003
    ..These data add to the growing list of tumor antigens that appear to be translated in two frames, and suggest that OGFr and OGFr-ARF may be useful targets for vaccination...
  38. ncbi request reprint Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
    Robert Soiffer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3343-50. 2003
    ..We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer...
  39. ncbi request reprint Involvement of interleukin-3 in delayed-type hypersensitivity
    N Mach
    Department of Medicine, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 91:778-83. 1998
    ..These findings reveal a critical role for IL-3 in some forms of delayed-type hypersensitivity...
  40. pmc Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
    C J Wu
    Center for Hematologic Oncology, and Department of Biostatistical Science, Dana Farber Cancer Institute, and Department of Medicine, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 106:705-14. 2000
    ..The characterization of B cell-defined antigens may help identify clinically relevant targets of the GVL response in vivo...
  41. pmc ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:6919-24. 2002
    ..Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors...
  42. doi request reprint Capitalizing on the immunogenicity of dying tumor cells
    Catia Fonseca
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:1603-8. 2008
    ....
  43. pmc TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells
    Norimoto Kobayashi
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Immunity 27:927-40. 2007
    ..These results show that TIM-4 and TIM-1 are immunologically restricted members of the group of receptors whose recognition of PS is critical for the efficient clearance of apoptotic cells and prevention of autoimmunity...
  44. doi request reprint The immune response to tumors
    Michael Dougan
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Curr Protoc Immunol . 2009
    ..Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients...
  45. ncbi request reprint Dual roles for immunity in gastrointestinal cancers
    Cristina Ferrone
    Dana Farber Cancer Institute, 44 Binney St, Dana 520C, Boston, MA 02115, USA
    J Clin Oncol 28:4045-51. 2010
    ..Here, we discuss the dual roles of immunity in cancer development, focusing on gastrointestinal malignancies, given the depth of recent insights into the mechanisms underlying these tumors...
  46. ncbi request reprint CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity
    Edward E S Nieuwenhuis
    Gastrointestinal Division, Brigham and Women s Hospital, Boston, MA, USA
    Exp Dermatol 14:250-8. 2005
    ..Thus, pharmacologic antagonists of CD1d can be used as effective inhibitors of CHS, a prototype for a variety of delayed-type tissue hypersensitivity responses...
  47. doi request reprint Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 68:8889-98. 2008
    ..Together, these findings delineate pleiotropic roles for MFG-E8 in the tumor microenvironment and raise the possibility that systemic MFG-E8 blockade might prove therapeutic for melanoma patients...
  48. doi request reprint Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival
    Saied Mirshahidi
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, United States
    Vaccine 27:1825-33. 2009
    ..We show that an OSP vaccination approach can assist in the disruption of self-tolerance and conclude that our approach may hold promise for immunoprevention of early-stage cancers in a general population...
  49. ncbi request reprint In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury
    Jean Louis Frossard
    Department of Surgery, Beth Israel Hospital Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Physiol Lung Cell Mol Physiol 283:L541-8. 2002
    ..Our findings indicate that GM-CSF plays a critical role in coupling pancreatitis to ALI and suggest that GM-CSF may act indirectly by regulating the release of other proinflammatory factors including MIP-2...
  50. ncbi request reprint Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
    Roberto Bellucci
    Dana Farber Cancer Institute, M530, 44 Binney St, Boston, MA 02115, USA
    Blood 103:656-63. 2004
    ..The expression of these genes was evaluated in primary myeloma cells and in normal plasma cells. This study demonstrates that the GVM response is associated with antibody responses to highly expressed myeloma-associated antigens...
  51. ncbi request reprint Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
    Ravi Salgia
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA
    J Clin Oncol 21:624-30. 2003
    ..To test whether this vaccination strategy enhances antitumor immunity in patients with metastatic non-small-cell lung cancer (NSCLC), we conducted a phase I clinical trial...
  52. pmc MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:1285-90. 2008
    ..Together, these findings reveal that the alterations in the NKG2D pathway are associated with the progression from MGUS to MM and raise the possibility that anti-MICA monoclonal antibodies might prove therapeutic for these disorders...
  53. ncbi request reprint The therapeutic implications of intratumoral regulatory T cells
    Glenn Dranoff
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8226-9. 2005
  54. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009
    ....
  55. doi request reprint Modeling genomic diversity and tumor dependency in malignant melanoma
    William M Lin
    Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 68:664-73. 2008
    ..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors...
  56. ncbi request reprint Triggering tumor immunity through angiogenesis targeting
    Masahisa Jinushi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institutel, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:3762-4. 2007
  57. ncbi request reprint High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  58. ncbi request reprint CTLA-4 blockade: unveiling immune regulation
    Glenn Dranoff
    J Clin Oncol 23:662-4. 2005
  59. ncbi request reprint Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity
    Taylor Sittler
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Clin Cancer Res 14:3896-905. 2008
    ..We sought to identify targets of responses from this vaccination strategy...
  60. ncbi request reprint Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 66:3294-302. 2006
    ..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system...
  61. ncbi request reprint IL-7 induces myelopoiesis and erythropoiesis
    Francesca B Aiello
    Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, MD 21702, USA
    J Immunol 178:1553-63. 2007
    ..This study demonstrates that IL-7 can promote nonlymphoid hemopoiesis and production of cytokines active in the host defense system in vivo, supporting its possible clinical utility...
  62. ncbi request reprint Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation
    Takanori Teshima
    Department of Internal Medicine, University of Michigan Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Cancer Res 62:796-800. 2002
    ..This strategy has important implications to prevent recurrence of malignancies after BMT...
  63. pmc Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells
    Tamiko R Katsumoto
    Department of Pediatrics, University of California, San Francisco, CA 94143, USA
    J Exp Med 201:853-8. 2005
    ..These data demonstrate a nonredundant function of GM-CSF in radioprotection by donor hematopoietic cells that may prove relevant in clinical transplantation...
  64. ncbi request reprint Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3
    Armin G Jegalian
    Department of Molecular and Medical Pharmacology, Molecular Biology Institute, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1735, USA
    Blood 99:2603-5. 2002
    ..These results suggest EpoR haploinsufficiency and promotion of in vivo erythropoiesis by GM-CSF and IL-3...

Research Grants14

  1. Targeting MFG-E8 as Melanoma Immunotherapy
    Glenn Dranoff; Fiscal Year: 2010
    ..Work in this project will clarify the ways in which MFG-E8 blockade accomplishes melanoma killing, which in turn should support the development of MFG-E8 targeted treatments for melanoma patients. ..
  2. Targeting MFG-E8 as Melanoma Immunotherapy
    Glenn Dranoff; Fiscal Year: 2011
    ..Work in this project will clarify the ways in which MFG-E8 blockade accomplishes melanoma killing, which in turn should support the development of MFG-E8 targeted treatments for melanoma patients. ..
  3. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2001
    ..2. To evaluate the ability of GM-CSF and IL-3 deficient mice to process exogenous antigens for MHC class I presentation. 3. To evaluate the functions of GM-CSF and IL-3 in promising cancer vaccination strategies. ..
  4. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2006
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  5. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2009
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  6. Targets of Immune-Mediated Tumor Destruction
    Glenn Dranoff; Fiscal Year: 2007
    ..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
  7. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2004
    ..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
  8. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2003
    ..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
  9. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2002
    ..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
  10. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 2000
    ..2. To evaluate the ability of GM-CSF and IL-3 deficient mice to process exogenous antigens for MHC class I presentation. 3. To evaluate the functions of GM-CSF and IL-3 in promising cancer vaccination strategies. ..
  11. CSF DEFICIENCY AND ANTITUMOR IMMUNITY
    Glenn Dranoff; Fiscal Year: 1999
    ..2. To evaluate the ability of GM-CSF and IL-3 deficient mice to process exogenous antigens for MHC class I presentation. 3. To evaluate the functions of GM-CSF and IL-3 in promising cancer vaccination strategies. ..